bintrafusp alfa + cisplatin + paclitaxel + bevacizumab

This is a **combination regimen** consisting of bintrafusp alfa, cisplatin, paclitaxel, and bevacizumab, evaluated in clinical settings primarily for advanced or metastatic cancers. **Bintrafusp alfa** is a bifunctional fusion protein combining a transforming growth factor beta (TGF-β) "trap" (extracellular domain of TGFβ receptor II) with an anti-programmed death-ligand 1 (PD-L1) human monoclonal IgG1 antibody, thus targeting both PD-L1 and TGF-β signaling to enhance antitumor immunity[1][3][5]. **Cisplatin** is a platinum-based cytotoxic chemotherapeutic agent that induces inter- and intra-strand DNA crosslinking, resulting in apoptosis in rapidly dividing tumor cells. **Paclitaxel** is a taxane chemotherapeutic that stabilizes microtubules and prevents cell division, leading to apoptosis. **Bevacizumab** is a humanized monoclonal antibody inhibiting vascular endothelial growth factor A (VEGF-A), thereby blocking angiogenesis and depriving tumors of necessary blood supply[2][4][8]. This combination therapy is being assessed for synergy of immune checkpoint inhibition, TGF-β pathway blockade, cytotoxic chemotherapy, and anti-angiogenic activity, mainly in advanced cervical, biliary tract, and other solid tumors.